PROK
ProKidney Corp.
$1.82
-0.55%
2026-06-22
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Key Fundamentals
Forward P/E
-2.61
EPS (TTM)
$-0.52
ROE
-43.2%
Revenue Growth (YoY)
196.1%
Profit Margin
0.0%
Debt/Equity
1.34
Beta
1.75
Market Cap
$575.2M
Avg Volume (10D)
571K
Recent Breakout Signals
No recent breakout signals detected for PROK.
Recent Price Range (60 Days)
60D High
$2.19
60D Low
$1.53
Avg Volume
940K
Latest Close
$1.82
Get breakout alerts for PROK
Sign up for Breakout Scanner to receive daily notifications when PROK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
ProKidney Corp. (PROK) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors PROK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. PROK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.